BioPharma Resources

Drug Trial Radar · NCT05745207

A Study To Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2086 in Healthy Adult and Elderly Participants

A First-In-Human, Two-Part Randomized, Double-Blind, Placebo-Controlled, Single-Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2086 in Healthy Adult and Elderly Subjects

Last checked: Nov 19, 2026Latest source record: Oct 2, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

53

Actual

Start

Feb 20, 2023

Primary completion

Jan 18, 2024

Study completion Jan 18, 2024

Sponsor

Lead sponsor
Eisai Inc.Eisai
Sponsor type
Industry
First posted
Feb 27, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Other
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The primary objective of this study is to evaluate the safety and tolerability of E2086 following administration of a single oral doses in healthy adult and elderly participants.

Conditions

  • Healthy Volunteers

Interventions

  • E2086Drug

    E2086 tablets.

  • PlaceboDrug

    E2086 matched placebo tablets.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Treatment-emergent Adverse Events (TEAEs)Time frame: From Screening up to 10 days
  2. Number of Participants With Serious Adverse Events (SAEs)Time frame: From Screening up to 10 days
  3. Number of Participants With Clinically Significant Abnormal Laboratory ValuesTime frame: From Screening up to 10 days
  4. Number of Participants With Clinically Significant Abnormal Vital Signs ValuesTime frame: From Screening up to 10 days
  5. Number of Participants With Clinically Significant Abnormal Electrocardiograms (ECGs) FindingsTime frame: From Screening up to 10 days
  6. Number of Participants With Suicidal Ideation or Suicidal Behavior as Measured Using Columbia-suicide Severity Rating Scale (C-SSRS)Time frame: From Screening up to 10 days
  7. Number of Participants With Clinically Significant Abnormal Physical Examination FindingsTime frame: From Screening up to 10 days
  8. Number of Participants With Clinically Significant Abnormal Neurological Examination FindingsTime frame: From Screening up to 10 days
  9. Number of Participants With Clinically Significant Abnormal Electroencephalogram (EEG) FindingsTime frame: Baseline, Days 1 and 2

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Worldwide Clinical Trials

    San Antonio, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.